Bio-Rad Laboratories (BIO) EBITDA Margin (2009 - 2026)
Bio-Rad Laboratories' (BIO) quarterly EBITDA Margin came in at 5.76% in Q1 2026, up 171.0% year-on-year from 2.13% in Q1 2025, and up 133.58% on a QoQ basis from 17.15% in Q4 2025.
Bio-Rad Laboratories (BIO) EBITDA Margin (2009 - 2026) Analysis & Trends
Bio-Rad Laboratories (BIO) has 18 years of EBITDA Margin data on file, last reported at 5.76% in Q1 2026.
- On a quarterly basis, EBITDA Margin rose 171.0% year-over-year to 5.76% in Q1 2026; TTM through Mar 2026 was 2.22%, a 754.0% decrease from a year earlier, with the FY2025 full-year figure at 1.83%, down 865.0% from the prior year.
- EBITDA Margin for Q1 2026 stood at 5.76%, up from 17.15% in the prior quarter.
- Over the last five years, EBITDA Margin for BIO reached as high as 20.91% in Q1 2022 and fell as low as 17.15% in Q4 2025.
- Historically, EBITDA Margin has averaged 10.35% across 5 years, with a median of 11.83% in 2025.
- Across the five-year window, EBITDA Margin surged 703 bps in 2022 and slumped 2589 bps in 2025, its largest moves.
- Year by year, EBITDA Margin stood at 16.25% in 2022, then decreased by 14 bps to 13.99% in 2023, then plunged by 38 bps to 8.73% in 2024, then plunged by 296 bps to 17.15% in 2025, then jumped by 134 bps to 5.76% in 2026.
- Per Business Quant data, the three most recent EBITDA Margin figures were 5.76% in Q1 2026, 17.15% in Q4 2025, and 10.0% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 181.19 Bn | 173.90 Bn | 6.27 Bn | 12.05% |
| 2 | Stryker | 128.53 Bn | 125.65 Bn | 3.81 Bn | 15.55% |
| 3 | Medtronic | 107.77 Bn | 98.55 Bn | 6.41 Bn | 19.10% |
| 4 | Boston Scientific | 67.72 Bn | 66.27 Bn | 3.61 Bn | 21.16% |
| 5 | Edwards Lifesciences | 48.21 Bn | 44.54 Bn | 1.29 Bn | 28.97% |
| 6 | Dexcom | 28.41 Bn | 27.29 Bn | 750.30 Mn | 21.42% |
| 7 | GE HealthCare Technologies | 28.33 Bn | 26.05 Bn | 1.98 Bn | 10.04% |
| 8 | Smith & Nephew | 26.76 Bn | 26.18 Bn | - | - |
| 9 | Koninklijke Philips | 25.27 Bn | 22.15 Bn | 2.07 Bn | 6.17% |
| 10 | Bio-Rad Laboratories | 8.49 Bn | 6.92 Bn | 309.40 Mn | 5.76% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 5.76% |
| Dec 31, 2025 | -17.15% |
| Sep 30, 2025 | 10.00% |
| Jun 30, 2025 | 11.83% |
| Mar 31, 2025 | 4.05% |
| Dec 31, 2024 | 8.73% |
| Sep 30, 2024 | 9.93% |
| Jun 30, 2024 | 15.90% |
| Mar 31, 2024 | 7.30% |
| Dec 31, 2023 | 13.99% |
| Sep 30, 2023 | 14.39% |
| Jun 30, 2023 | 13.16% |
| Mar 31, 2023 | 9.15% |
| Dec 31, 2022 | 16.25% |
| Sep 30, 2022 | 13.90% |
| Jun 30, 2022 | 17.78% |
| Mar 31, 2022 | 20.91% |
| Dec 31, 2021 | 16.09% |
| Sep 30, 2021 | 20.99% |
| Jun 30, 2021 | 17.43% |